Original Article

You have full text access to this OnlineOpen article

Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma

  1. Yehuda Z. Patt M.D.1,†,‡,*,
  2. Manal M. Hassan M.D., M.P.H., Ph.D.1,
  3. Alvaro Aguayo M.D.2,
  4. Ajay K. Nooka M.B.B.S., M.P.H.1,2,3,4,
  5. Richard D. Lozano R.Ph.1,2,3,4,
  6. Steven A. Curley M.D.3,
  7. Jean-Nicolas Vauthey M.D.3,
  8. Lee M. Ellis M.D.3,
  9. Isac I. Schnirer M.D.1,2,3,4,
  10. Robert A. Wolff M.D.1,
  11. Chusilp Charnsangavej M.D.4,
  12. Thomas D. Brown M.D.1,2,3,4

Article first published online: 28 JUN 2004

DOI: 10.1002/cncr.20368

Issue

Cancer

Cancer

Volume 101, Issue 3, pages 578–586, 1 August 2004

Additional Information

How to Cite

Patt, Y. Z., Hassan, M. M., Aguayo, A., Nooka, A. K., Lozano, R. D., Curley, S. A., Vauthey, J.-N., Ellis, L. M., Schnirer, I. I., Wolff, R. A., Charnsangavej, C. and Brown, T. D. (2004), Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer, 101: 578–586. doi: 10.1002/cncr.20368

Author Information

  1. 1

    Department of Gastrointestinal Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

  2. 2

    Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

  3. 3

    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

  4. 4

    Department of Diagnostic Radiology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

  1. †

    The University of Maryland Greenebaum Cancer Center, Baltimore, Maryland

  1. ‡

    Fax: (410) 328-0805

*The University of Maryland Greenebaum Cancer Center, 22 South Greene Street, Baltimore, MD 21201-1595

Publication History

  1. Issue published online: 19 JUL 2004
  2. Article first published online: 28 JUN 2004
  3. Manuscript Accepted: 20 APR 2004
  4. Manuscript Revised: 13 APR 2004
  5. Manuscript Received: 12 DEC 2003

Funded by

  • Roche Pharmaceuticals (Nutley, NJ)

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (101K)

REFERENCES

  • 1
    El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999; 340: 745–750.
  • 2
    El-Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med. 2000; 160: 3227–3230.
  • 3
    Akriviadis EA, Llovet JM, Efremidis SC, et al. Hepatocellular carcinoma. Br J Surg. 1998; 85: 1319–1331.
    Direct Link:
  • 4
    Friedman MA. Primary hepatocellular cancer—present results and future prospects. Int J Radiat Oncol Biol Phys. 1983; 9: 1841–1850.
  • 5
    Lin DY, Lin SM, Liaw YF. Non-surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol. 1997; 12: S319–S328.
    Direct Link:
  • 6
    Lai CL, Wu PC, Chan GC, Lok AS, Lin HJ. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer. 1988; 62: 479–483.
    Direct Link:
  • 7
    Melia WM, Johnson PJ, Williams R. Induction of remission in hepatocellular carcinoma. A comparison of VP 16 with Adriamycin. Cancer. 1983; 5: 206–210.
    Direct Link:
  • 8
    Patt YZ, Hoque A, Roh M, et al. Durable clinical and pathologic response of hepatocellular carcinoma to systemic and hepatic arterial administration of platinol, recombinant interferon alpha 2B, doxorubicin, and 5-fluorouracil: a communication. Am J Clin Oncol. 1999; 22: 209–213.
  • 9
    Leung TW, Patt YZ, Lau WY, et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res. 1999; 5: 1676–1681.
  • 10
    Aguayo A, Patt YZ. Liver cancer. Clin Liver Dis. 2001; 5: 479–507.
  • 11
    Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United Sates. Hepatology. 2001; 33: 1353–1357.
    Direct Link:
  • 12
    Price P. Cholangiocarcinoma and the role of radiation and chemotherapy. Hepatogastroenterology. 2001; 48: 51–52.
  • 13
    Ahrendt SA, Nakeeg A, Pitt HA. Cholangiocarcinoma. Clin Liver Dis. 2001; 5: 191–218.
  • 14
    Martin RF, Rossie RL. Multidisciplinary considerations for patients with cancer of the pancreas or biliary tract. Surg Clin North Am. 2000; 80: 709–728.
  • 15
    Torok N, Gores GJ. Cholangiocarcinoma. Semin Gastrointest Dis. 2001; 12: 125–132.
  • 16
    Schauer RJ, Meyer G, Baretton G, Schildberg FW, Rau HG. Prognostic factors and long-term results after surgery for gallbladder carcinoma: a retrospective study of 127 patients. Langenbecks Arch Surg. 2001; 386: 110–117.
  • 17
    Patt YZ, Hassan MM, Lozano RD, et al. Phase II trial of cisplatin, interferon α-2b, doxorubicin, and 5-fluorouracil for biliary tract cancer. Clin Cancer Res. 2001; 7: 3375–3380.
  • 18
    Ishikawa T, Utoh M, Sawada N, et al. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol. 1998; 55: 1091–1097.
  • 19
    Schuller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol. 2000; 45: 291–297.
  • 20
    Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer. 1998; 34: 1274–1281.
  • 21
    Saeki T, Takashima S. [Mechanism and possible biochemical modulation of capecitabine (Xeloda), a newly generated oral fluoropyrimidine]. Gan To Kagaku Ryoho. 1999; 26: 447–455.
  • 22
    Endo M, Shinbori N, Fukase Y, et al. Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5′-deoxy-5-fluoroudine by cyclophosphamide in mammary tumor models. Int J Cancer. 1999; 83: 127–134.
    Direct Link:
  • 23
    Twelves C, Gynne-Jones R, Cassidy J, et al. Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Clin Cancer Res. 1999; 5: 1696–1702.
  • 24
    Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized Phase III study. J Clin Oncol. 2001; 19: 2282–2292.
  • 25
    Borner MM, Dietrich D, Stupp R, et al. Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol. 2002; 20: 1759–1766.
  • 26
    World Health Organization. WHO handbook for reporting results of cancer treatment. Geneva: World Health Organization, 1979.
  • 27
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457–481.
  • 28
    Gehan EA. A generalized Wilcoxon test for comparing arbitrarily single censored samples. Biometrics. 1965; 52: 203–223.
  • 29
    Lee ET. Statistical methods for survival analysis. New York: John Wiley & Sons, 1992.
  • 30
    CLIP Investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Lung Italian Program Investigators. Hepatology. 1998; 28: 751–755.
  • 31
    Farinati F, Rinaldi M, Gianni M, Naccarato R. How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system. Cancer. 2000; 89: 2266–2273.
    Direct Link:
  • 32
    Ueno S, Tanabe G, Sako K, et al. Discrimination value of the new Western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Hepatology. 2001; 34: 529–534.
    Direct Link:
  • 33
    Patt YZ, Jones DV Jr., Hoque A, et al. Phase II trial of intravenous flourouracil [sic] and subcutaneous interferon alfa-2b for biliary tract cancer. J Clin Oncol. 1996; 14: 2311–2315.
  • 34
    Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by Taxol/Taxotere in human cancer xenografts. Clin Cancer Res. 1998; 4: 1013–1019.
  • 35
    Bajetta E, DiBartolomeo M, Mariani L, et al. Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first line treatment in metastatic colorectal carcinoma. Cancer. 2004; 100: 279–287.
    Direct Link:
  • 36
    Patt YZ, Hassan MM, Lozano RD, et al. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol. 2003; 21: 421–427.
  • 37
    Patt YZ, Hassan M, Lozano R, et al. Phase II study of thalidomide for the treatment of hepatocellular carcinoma [abstract]. Proc Am Soc Clin Oncol. 2000; 14 Suppl 12: 1035.
  • 38
    Sgonc R, Fuerhapter C, Boeck G, Swerlick R, Fritsch P, Sepp N. Induction of apoptosis in human dermal microvascular endothelial cells and infantile hemangiomas by interferon-alpha. Int Arch Allergy Immunol. 1998; 117: 209–214.
  • 39
    Dinney CP, Bielenberg DR, Perrotte P, et al. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res. 1998; 58: 808–814.
  • 40
    Ishikawa T, Sekiguchi F, Fukase Y, Sawada N, Ishitsuka H. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res. 1998; 58: 685–690.
View Full Article (HTML) Get PDF (101K)